3月5日，宣布重磅交易的中国生物制药（01177.HK）盘中股价一度涨逾7%，最终收涨3.5%，报5.91港元/股。 此次引发广泛关注的交易源于前一日的一则公告。3月4日，中国生物制药宣布，公司附属公司正大天晴药业集团股份有限 公司（以下简称"正大天晴"）已与赛诺菲（Sanofi S.A.）的一家全资附属公司Sanofi就JAK/ROCK抑制剂罗伐昔替尼在全球 的开发、生产及商业化签订独家授权协议。 值得一提的是，此次交易标的并非处于早期的研发管线资产，而是一款已上市的成熟产品。罗伐昔替尼（商品名：安煦） 已于今年2月获得中国国家药品监督管理局批准上市，用于中危-2或高危的原发性骨髓纤维化（PMF）、真性红细胞增多 症后骨髓纤维化（PPV-MF）或原发性血小板增多症后骨髓纤维化（PET-MF）成年患者的一线治疗。 北京中医药大学卫生健康法治研究与创新转化中心主任邓勇向北京商报记者表示，与多数早期管线授权不同，本次交易标 的为已上市成熟资产，大幅降低跨国药企合作风险，体现国际巨头对中国创新药临床开发、注册申报与商业化能力的高度 认可。对中国生物制药而言，大额首付款与里程碑付款可快速回流资金，反哺研发体系，同时以 ...

| 代码 | 名称 | 现价 | 涨跌 | 涨跌幅▼ | | --- | --- | --- | --- | --- | | 688027 | 国盾量子 | 721.10 | 78.48 | 12.21% | | 300502 | 新易盛 | 412.77 | 43.40 | 11.75% | | 301307 | 美利信 | 37.01 | 3.80 | 11.44% | | 600775 | 南京熊猫 | 14.92 | 1.36 | 10.03% | | 002796 | 世嘉科技 | 57.32 | 5.21 | 10.00% | | 300689 | 澄天伟业 | 48.53 | 3.30 | 7.30% | | 300205 | *ST天响 | 4.84 | 0.31 | 6.84% | | 300308 | 中际旭创 | 573.45 | 34.45 | 6.39% | | 600105 | 永鼎股份 | 28.35 | 1.55 | 5.78% | | 300710 | 万隆光电 | 30.91 | 1.69 | 5.78% | | 300578 | 会畅科技 | 22.73 | 1.21 | ...

根据协议，中国生物制药及子公司正大天晴药业将授予赛诺菲该产品在全球范围内开发、生产与商业化 的独家权利，同时将获得1.35亿美元的首付款、以及最高13.95亿美元的潜在开发、监管及销售里程碑付 款，及最高双位数的销售分成。这是中国药企在移植领域创下的最大规模对外授权交易。 有券商表示，中国创新药License-out交易总额从2017年的25.62亿美元增长至2025年的1402.74亿美元， 2026年初总额已达2025年的22%，反映国际竞争力增强；2025年超70%的创新药企业实现收入正增长， 行业逐步进入商业化收获期；当前医药板块估值性价比明显，建议关注具备出海确定性机会及细分赛道 具备临床数据优势的企业。 资料显示，港股通医疗ETF富国（159506）紧密跟踪恒生港股通创新药及医疗保健指数，根据指数编制 方案，成分股研发支出占比及创新药业务占比较高，最近两年平均研究开发/收入排名位列最低的公司 会被剔除，创新属性突出，帮助投资者精准捕捉港股医药板块投资机会。 每日经济新闻 港股早盘震荡走强，创新药概念股盘中持续拉升，MIRXES-B涨超7%，科伦博泰生物-B、中国生物制 药涨超6%，再鼎医药、映恩生 ...

Group 1 - The core viewpoint of the news is that the Hong Kong pharmaceutical sector is experiencing a rebound, particularly in innovative drug stocks, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% after a period of decline [1][4] - The Hong Kong Stock Connect Innovative Drug ETF (520880) recorded five consecutive days of decline, reaching a historical low, but saw a capital inflow of over 135 million yuan during this period [1][2] - The healthcare sector in Hong Kong is showing signs of recovery, with major stocks like WuXi Biologics and BeiGene contributing to the rise of the Hong Kong Stock Connect Healthcare ETF [4][6] Group 2 - The total amount of business development (BD) for innovative drugs in China exceeded 50 billion USD in the first two months of 2026, with upfront payments surpassing 3 billion USD, indicating a strong growth trajectory [3] - Chinese pharmaceutical companies are entering a commercialization phase, with companies like Rongchang Bio turning a profit of 709 million yuan in 2025, and BeiGene achieving its first non-GAAP net profit [3] - China National Pharmaceutical Group's stock surged over 5% following the announcement of an exclusive licensing agreement with Sanofi, which includes an upfront payment of 135 million USD and potential milestone payments of up to 1.395 billion USD [1][3]

（文章来源：每日经济新闻） 每经AI快讯，3月5日，中国生物制药(01177.HK)涨超5%，截至发稿涨5.25%，报6.01港元，成交额1.46 亿港元。 ...

Core Viewpoint - China Biologic Products (01177) has seen a stock increase of over 5% following the announcement of an exclusive licensing agreement with Sanofi for the innovative oral small molecule JAK/ROCK inhibitor, Roflumilast, with potential payments exceeding $1.53 billion [1] Group 1: Financial Impact - The agreement allows China Biologic's subsidiary, Chengda Tianqing, to grant Sanofi exclusive rights for the global development, production, and commercialization of Roflumilast [1] - China Biologic is entitled to receive up to $1.53 billion in payments, which includes an upfront payment of $135 million and potential milestone payments based on development, regulatory, and sales achievements [1] - Additionally, the company will receive tiered royalties based on the annual net sales of Roflumilast, with a maximum double-digit percentage [1] Group 2: Market Reaction - Following the announcement, China Biologic's stock rose by 5.25%, reaching HKD 6.01, with a trading volume of HKD 146 million [1] - The stock performance indicates positive market sentiment regarding the potential financial benefits from the licensing agreement [1] Group 3: Regulatory Considerations - The effectiveness of the agreement is subject to customary closing conditions, including the approval from relevant regulatory authorities [1]

3月5日早盘，港股医药终于反弹！创新药龙头普涨，100%创新药研发标的——港股通创新药ETF （520880）高开高走，现涨超3%。昨日，520880录得五连跌，场内价格创下历史新低，不过资金逆行 增仓，连续5日低吸合计逾1.35亿元。 投创新药，认准港股通创新药ETF（520880）及其场外联接基金（025221），100%布局创新药研发类 公司，前十大权重股占比超七成，龙头属性突出。 注： ETF 基金不收取销售服务费。投资者在申购或赎回基金份额时，申购赎回代理券商可按照不超过 0.5% 的标准收取佣金，其中包含证券交易所、登记机构等收取的相关费用。基金费率详见各基金法律 文件。 | 分时 多日 1分 · | | | | | F9 盘前盘后 露加 九粒 酒线 工具 (8 (7) > | | | | | | 港股通创新药ETF ① | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.468 | | | 520880[用胶通创新的ETF] 10:06 价 0.468 新跌 ...

2026 年 3 月 5 日 星期四 ➢ 每日大市点评 昨日港股扩大跌幅。特朗普表示，美国将派军舰为途经霍尔木兹海峡的油轮提供护航。这原则上有利稳定原油价格，或 因此导致石油股回调。可是其他板块也普遍下跌，相关投资信心似乎仍明显受到美以伊战争影响。恒生指数及国企指数 分别收报 25,249.48 点及 8,483.95 点，分别下跌 2.0%及 1.5%。港股成交合共 3,643 亿港元，较前日的 3,705 亿港元，下 跌 1.7%。分类指数方面，资讯科技、电讯、原材料业指数分别仅下跌 0.4%、0.5%、0.8%；综合企业、金融、医疗保健则 分别下跌 4.0%、2.9%、2.4%。蓝筹个股方面，中国宏桥(1378 HK)及信义光能(968 HK)领涨，分别上升 6.0%及 4.2%；友 邦保险(1299 HK)及药明生物(2269 HK)领跌，分别下跌 4.8%及 4.6%。 商品价格表现分化，或反映投资者看法渐有分歧。金价重返 5,100 美元以上水平。WTI 原油价格在 76 美元水平上下波动。 TTF 期货气价则回落至 50 欧元水平。如果战争扩大或持续，预料上游资源价格将再次上涨，相关资源供应也受 ...

中国生物制药(01177)涨超5%，暂领升蓝筹。截至发稿，涨5.25%，报6.01港元，成交额1.46亿港元。 消息面上，中国生物制药日前宣布，与赛诺菲就罗伐昔替尼，一款全球首创(First-in-Class)的新型、强 效口服小分子JAK/ROCK抑制剂达成独家授权协议。根据协议，中国生物制药子公司正大天晴授予赛诺 菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。中国生物制药有权获得最高15.3亿美元的 付款，其中包括1.35亿美元的首付款以及潜在开发、监管及销售里程碑付款，另外还将获得基于罗伐昔 替尼年度净销售额的最高双位数的阶梯式特许权使用费。协议的生效以惯常的交割条件为前提，包括取 得相关监管部门的批准。 ...

Core Viewpoint - The collaboration between China National Pharmaceutical Group and Sanofi for the exclusive licensing of Rovaxitinib represents a significant milestone for Chinese biopharmaceutical innovation, with a total potential payment of up to $1.53 billion, including an upfront payment of $135 million, which will greatly enhance the company's cash flow and support future R&D investments [1][5][6]. Group 1: Licensing Agreement Details - The agreement allows Sanofi to develop, manufacture, and commercialize Rovaxitinib globally, marking a shift in the valuation of Chinese biopharmaceutical companies from generic leaders to innovative platform companies [1][6]. - The total payment structure includes milestone payments based on development, regulatory, and sales achievements, along with a tiered royalty based on annual net sales [1][5]. Group 2: Market Context and Trends - The licensing deal is part of a broader trend in the Chinese biopharmaceutical sector, where the total value of outbound licensing agreements reached $135.655 billion in 2025, with 157 transactions, indicating a historical high in the market [6][7]. - Major pharmaceutical companies are increasingly seeking to acquire late-stage assets from China to mitigate the risks associated with internal R&D, especially in light of impending patent cliffs between 2025 and 2030 [6][7]. Group 3: Clinical and Commercial Potential - Rovaxitinib has shown promising results in treating primary myelofibrosis and chronic graft-versus-host disease (cGVHD), with ongoing clinical trials indicating superior efficacy compared to existing therapies [5][6]. - The drug's approval in China and its subsequent global licensing is seen as a validation of the quality of Chinese innovative drugs, transitioning from a follower to a leader in the global pharmaceutical landscape [5][6]. Group 4: Future Market Dynamics - The trend in biopharmaceutical deals is shifting from single product licensing to comprehensive platform and multi-product agreements, reflecting a more strategic approach to collaboration [10][11]. - The focus is expected to move from merely increasing the number of deals to enhancing the quality and clinical value of the assets involved, with companies that can consistently deliver high-quality projects gaining a competitive edge [11][12].